|Other Names||NKG2D ligand 2, N2DL-2, NKG2DL2, ALCAN-alpha, Retinoic acid early transcript 1H, UL16-binding protein 2, ULBP2, N2DL2, RAET1H|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity.|
|Cellular Location||Cell membrane; Lipid-anchor, GPI-anchor Endoplasmic reticulum. Secreted. Note=In CMV-infected fibroblasts, detected in the endoplasmic reticulum/cis-Golgi|
|Tissue Location||Expressed in various types of cancer cell lines and in the fetus, but not in normal tissues|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Ligand for the NKG2D receptor, together with at least ULBP1 and ULBP3. ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. Binding of ULBPs ligands to NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway. In CMV infected cells, interacts with soluble CMV glycoprotein UL16. The interaction with UL16 blocked the interaction with the NKG2D receptor, providing a mechanism by which CMV infected cells might escape the immune system. UL16 also causes ULBP2 to be retained in the ER and cis-Golgi apparatus so that it does not reach the cell surface.
McGilvray, R.W., et al. Int. J. Cancer 127(6):1412-1420(2010)Nuckel, H., et al. Leukemia 24(6):1152-1159(2010)Antoun, A., et al. Hum. Immunol. 71(6):610-620(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)Ward, J., et al. PLoS Pathog. 5 (10), E1000613 (2009) :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.